NEWS
Rongjia Medical adheres to the original intention and mission of "for human health"
Your location:
Homepage
-
-
-
The safety inspection passes the Beijing new crown inactivated vaccine production workshop can be put into production at any time

The safety inspection passes the Beijing new crown inactivated vaccine production workshop can be put into production at any time

  • Categories:Industry News
  • Author:
  • Origin:
  • Time of issue:2020-08-10 14:39
  • Views:

(Summary description)According to the latest news from Sinopharm Group, the new crown inactivated vaccine production workshop of the Beijing Institute of Biological Products has passed the joint biosafety inspection organized by relevant national departments and is qualified for use. Previously, the workshop had obtained a new crown vaccine production license.

The safety inspection passes the Beijing new crown inactivated vaccine production workshop can be put into production at any time

(Summary description)According to the latest news from Sinopharm Group, the new crown inactivated vaccine production workshop of the Beijing Institute of Biological Products has passed the joint biosafety inspection organized by relevant national departments and is qualified for use. Previously, the workshop had obtained a new crown vaccine production license.

  • Categories:Industry News
  • Author:
  • Origin:
  • Time of issue:2020-08-10 14:39
  • Views:
Information

According to the latest news from Sinopharm Group, the new crown inactivated vaccine production workshop of the Beijing Institute of Biological Products has passed the joint biosafety inspection organized by relevant national departments and is qualified for use. Previously, the workshop had obtained a new crown vaccine production license.

According to Sinopharm China Biotech, in the fight against the new crown epidemic, it has made a full attack on the three fronts of diagnosis, treatment, and prevention. It has achieved rapid and portable nucleic acid detection kits, plasma treatment methods for recovered patients, new crown-specific immunoglobulins and The new crown inactivated vaccine is a series of major innovations that lead the world.

  While fully advancing the research and development of vaccines, Sinopharm China Biological does not rely on it. It takes the initiative to play its role as the main body of the enterprise and builds high-level biosafety production facilities in two biological products research institutes in Beijing and Wuhan.

   The high-grade biosafety production facility in Beijing, which has just passed inspection, is currently the world's first and largest production workshop for inactivated COVID-19 vaccine. During the whole process of design, construction and use of the workshop, Sinopharm Group and Sino Biotech followed the relevant national and World Health Organization biosafety norms and standards, introduced domestic and foreign experienced design teams, learned from international advanced experience, and followed the biosafety level 3 Protection standards for construction, management and maintenance.

   With the strong support of the Beijing Municipal Government, the Beijing Institute of Biological Products completed the construction of the workshop on April 15 in only 2 months, creating the "Huoshenshan" speed of the construction of the new crown inactivated vaccine workshop.

   In mid-July, relevant national departments organized experts to conduct a comprehensive inspection of the biosafety of the new crown vaccine production workshop of the Beijing Institute of Biological Products. They believed that the production workshop basically met the requirements of the relevant national standards and could be put into mass production of the new crown vaccine.

   The high-grade biosafety facilities and supporting laboratory complex of Wuhan Institute of Biological Products of China National Biotechnology Co., Ltd. was completed on July 1 and reached the conditions for delivery and use at the end of July, and strive to obtain relevant inspections and production conditions as soon as possible. Wuhan Institute of Biological Products will also become the world's only biological product R&D and production unit with a high-level biosafety R&D laboratory and production facility complex.

   After the production workshops of the two research institutes are put into use, China Bio will be able to guarantee that the total annual production capacity of the new crown vaccine will reach 220 million doses.

Relevant information

There is currently no information to display
Please add data record on website background.

Yingtan Rongjia Group Medical Equipment
Industrial Co., Ltd.

Unified national service hotline: 

Company address:

Yujiang Industrial Park, Jiangxi Province

All rights reserved:Yingtan Rongjia Group Medical Equipment Industrial Co., Ltd.      Gan ICP No. 20010169   Powered by www.300.cn